Controversies in the management of infections in immunocompromised patients. Symposium. New York NY (USA), 1992/11/18.
Monoclonal antibodies directed against the endotoxins produced by gram-negative organisms have been developed for the treatment of patients with sepsis.
Phase 3 clinical trials in which two of these agents, ES and HA-1A, have been evaluated have suggested possible benefit in terms of improved survival and reversal of organ dysfunction for certain subgroups.
Since monoclonal antibodies are expected to be expensive, cost-effectiveness analysis is necessary to assess the joint clinical and economic impact.
Cost-effectiveness studies based on the clinical data from these phase 3 trials have suggested that monoclonal antibodies may represent a cost-effective approach to the treatment of sepsis.
Mots-clés Pascal : Endotoxine, Septicémie, Immunothérapie, Analyse coût efficacité, Economie santé, Homme, Anticorps monoclonal, Traitement
Mots-clés Pascal anglais : Endotoxin, Septicemia, Immunotherapy, Cost efficiency analysis, Health economy, Human, Monoclonal antibody, Treatment
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 94-0070925
Code Inist : 002B02S02. Création : 199406.